Cargando…

Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (AHST) for patients with HER2-positive metastatic breast cancer. Ten patients (9 women and 1 man) were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Yee Chung, Rondón, Gabriela, Anderlini, Paolo, Khouri, Issa F., Champlin, Richard E., Ueno, Naoto T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805996/ https://www.ncbi.nlm.nih.gov/pubmed/24155780 http://dx.doi.org/10.7150/jca.6775

Ejemplares similares

Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection
por: Marinos, Alejandro, et al.
Publicado: (2023)

Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
por: Ramdial, Jeremy L., et al.
Publicado: (2021)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
por: Zhang, Yanqiang, et al.
Publicado: (2022)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2014)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
por: Patel, Tejal A., et al.
Publicado: (2019)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
por: Hajjar, Ali, et al.
Publicado: (2019)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2019)

Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
por: Fu, Xiaomin, et al.
Publicado: (2018)

P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA
por: Pasvolsky, O., et al.
Publicado: (2022)

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
por: Akin, Serkan, et al.
Publicado: (2022)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2020)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
por: Toi, Masakazu, et al.
Publicado: (2017)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
por: Gori, S, et al.
Publicado: (2004)

Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report
por: Papageorgiou, Konstantinos I, et al.
Publicado: (2009)

Successful Treatment of HER2-neu–positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support
por: Smith, Julie
Publicado: (2012)

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
por: Baselga, J., et al.
Publicado: (2019)

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin
por: Yang, Canyu, et al.
Publicado: (2022)

Value of UGT2B7-161 Single Nucleotide Polymorphism in Predicting the Risk of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Who Underwent Pertuzumab Combined with Trastuzumab Therapy by PSL
por: Li, Jian, et al.
Publicado: (2022)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
por: Mego, Michal, et al.
Publicado: (2012)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report
por: Huang, Jiayi, et al.
Publicado: (2022)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Delayed Paclitaxel-Trastuzumab-Induced Interstitial Pneumonitis in Breast Cancer
por: Abulkhair, Omalkhair, et al.
Publicado: (2011)

Burst of Corneal Dendritic Cells during Trastuzumab and Paclitaxel Treatment
por: Sterenczak, Katharina A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v74e1asp9884cceurvf73ga1jq